Eli Lilly and Co (NYSE: LLY) stock lost over 4.2% on July 25^th, 2017 (As of 12:07PM EDT; Source: Google finance). The group along with Incyte reported that a resubmission to the FDA for their New Drug Application (NDA) for baricitinib, medicine for treating moderate-to-severe rheumatoid arthritis, would be delayed beyond 2017. This led to the stock fall this morning. Duration of resubmission for the NDA would depend on a minimum of 18 months. Moreover, the group cut their 2017 EPS to $2.51 to $2.61 range but enhanced 2017 non-GAAP EPS to the range of $4.10 to $4.20.

On the other side, the group reported a decent second quarter of 2017 performance, with worldwide revenue rising 8% yoy to $5.824 billion. Trulicity^® and other new products like Taltz^®, Basaglar^®, Jardiance^®, Lartruvo and Cyramza contributed to the performance. Taltz and Basaglar revenues enhanced 1,118% and 388% respectively in this year to date as compared to the prior corresponding period. Trulicity and Jardiance rose 147% and 126% respectively in this year to date against pcp. U.S. revenues rose 15% to $3.324 billion, driven by better-realized prices for many pharmaceutical products, on the back of Cialis and Forteo.

However, revenue outside the U.S. lost only 1 percent, to $2.500 billion, on the back of the loss of exclusivity of Zyprexa in Japan and Cymbalta^® in Canada and Europe, coupled with rising competition and lower realized prices and loss of exclusivity for Alimta in several countries.  Meanwhile, Gross margin rose 8%, to $4.273 billion, during the quarter from pcp driven by better-realized prices and manufacturing efficiencies, which offset negative product mix and rising expenses coming from new pharmaceutical products.

The group’s Pipeline comprises U.S. regulatory status update for baricitinib, Japan marketing approval for Olumiant, positive Phase 3 data for galcanezumab, Review designation for abemaciclib in the U.S. and Recent collaborations with Nektar Therapeutics and KeyBioscience.

Eli Lilly along with Nektar Therapeutics collaborated to co-develop NKTR-358, discovered by Nektar with first human dose clinical development in Phase 1 during March of 2017. The group would give a payment of $150 million to Nektar in 2017.They also made a new collaboration with KeyBioscience for developing of Dual Amylin Calcitonin Receptor Agonists (DACRAs), a potential new class of treatments for metabolic disorders such as type 2 diabetes. They would offer $55 million to KeyBioscience in the third quarter of 2017.